Status:
RECRUITING
Time Prediction and Cerebellum: Magnetic Transcranial Stimulation (TMS) in Healthy Volunteers
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
Schizophrenia
Eligibility:
All Genders
18-60 years
Brief Summary
The aim of the study is to check the role of the cerebellum in time prediction in healthy volunteers, by means of magnetic transcranial stimulation targeted on the cerebellum, and recording of behavio...
Eligibility Criteria
Inclusion
- Participant, male or female, between 18 and 60 years old
- Subject affiliated to a social health insurance scheme (beneficiary or entitled person)
- Subject who has dated and signed an informed consent form
- For a woman of childbearing age, negative pregnancy test and effective contraception throughout the study
Exclusion
- \- Participant with substance use disorders (as defined by DSM-V)
- Participants taking benzodiazepines and related substances (in the period before inclusion, for a duration equivalent to 5 half-lives of the product), cannabis (in the 2 months before inclusion) or hallucinogenic substances (in the period before inclusion, for a duration equivalent to 5 half-lives of the product).
- Participant with neurological pathology or sequelae
- Participant with Attention Deficit Hyperactivity Disorder (ADHD)
- Participant with a borderline personality disorder
- Participant with disabling sensory impairments, including visual acuity (corrected, if applicable) \< 0.8 (due to use of visual material) (Freiburg Vision Test, Bach 1996)
- Participant deprived of liberty or subject to the safeguard of justice
- Participant under guardianship or curatorship
- Participant in a period of exclusion defined by another clinical study or participant in a study that may impact on research results
- Pregnant or breastfeeding woman
- Subject with a contraindication to performing an MRI or TMS: presence of non-removable ferromagnetic body, prosthesis, pacemaker, medication delivered by an implanted pump, vascular clip or stent, heart valve or ventricular lead, certain intracerebral clips, cochlear implants, history of epilepsy, skin pathology at the point of contact with the electrodes.
- Subject with a history of major neurological or psychiatric illness with current psychotropic medication (i.e., antidepressant, thyroid regulator, antipsychotic, benzodiazepine and related drugs, or hypnotic).
Key Trial Info
Start Date :
October 10 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2025
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT04300946
Start Date
October 10 2021
End Date
October 1 2025
Last Update
August 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Strasbourg
Strasbourg, France